Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frederick Johnson

Vascular & Interventional Radiology Thomasville, GA Medical Doctor

NPI 1619143914 CMS profile 1303031

Po Box 5764, Thomasville, GA 31758

Open in the dashboard

General payments

$8,145

149 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frederick Johnson of Thomasville, GA is reported in the CMS Open Payments database as having received $8,145 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $902 26
2024 General $2,019 43
2023 General $2,138 29
2022 General $1,227 12
2021 General $654 17
2020 General $673 14
2019 General $533 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frederick Johnson
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Frederick Johnson were reported at $902. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Frederick Johnson Vascular & Interventional Radiology median Middle half National median
2019 $533 $422 $125–$1,555 $163
2020 $673 $200 $68–$652 $114
2021 $654 $280 $99–$866 $132
2022 $1,227 $433 $137–$1,497 $149
2023 $2,138 $506 $152–$2,019 $160
2024 $2,019 $556 $175–$1,930 $164
2025 $902 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $2,904 40 payments
  2. Penumbra, Inc. $1,600 22 payments
  3. Medtronic, Inc. $1,107 16 payments
  4. Stryker Corporation $553 8 payments
  5. Boston Scientific Corporation $431 10 payments
  6. AngioDynamics, Inc. $246 8 payments
  7. Globus Medical, Inc. $232 5 payments
  8. Shockwave Medical, Inc $159 8 payments
  9. Janssen Pharmaceuticals, Inc $156 4 payments
  10. AstraZeneca Pharmaceuticals LP $125 1 payment
  11. Other $632 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,087 134 payments
  2. Travel and Lodging $2,980 13 payments
  3. Education $79 2 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $2,983 41 payments
  2. CT THROMBECTOMY SYSTEM KIT $2,514 39 payments
  3. Indigo System $1,512 20 payments
  4. ELLIPSYS VASCULAR ACCESS SYSTEM $984 12 payments
  5. ClotTriever $291 4 payments
  6. FlowTriever $291 4 payments
  7. Senza $232 5 payments
  8. IVS - VERTEBRAL AUGMENTATION PRODUCTS $169 1 payment
  9. XARELTO $156 4 payments
  10. Indigo $147 2 payments
  11. Other $2,233 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

96

Median for Interventional Radiology: 38

Drug cost

$28,345

Median for Interventional Radiology: $333

Branded share of claims

72.9%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 27 $18,660
Xarelto Rivaroxaban Brand 15 $9,459
Clopidogrel Clopidogrel Bisulfate Brand 28 $142
Atorvastatin Calcium Generic 15 $71
Tramadol Hcl Generic 11 $13

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 126 billing codes

Paid by Medicare

$87,083

Medicare's payments for the services billed

Medicare patients

376

Average age 73

Services billed

969

171 women, 205 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 53%
Arthritis 51%
Heart failure 50%
Ischemic heart disease 48%
Diabetes 47%
COPD 33%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record